Drug intelligence / Profile preview

metformin + folic acid

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of metformin, an oral antidiabetic medication, and folic acid, an essential vitamin. This combination has been studied for its effects on insulin resistance, homocysteine levels, and inflammatory markers, particularly in obese children and adolescents. Metformin works by decreasing hepatic glucose production, reducing intestinal glucose absorption, and increasing insulin sensitivity, while folic acid plays crucial roles in cognitive function, DNA formation, and various other biological processes.

Other names: folic acid + metforminmetformin + folic acidmetformin + folate

Targets

DHFR (Dihydrofolate reductase)AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on metformin + folic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metformin + folic acid.

Explore the full profile